PTPN22 through the Regulation of Th17/Treg Balance Acts as a Potential Target for the Treatment of Graves’ Disease

Phosphotyrosine phosphatase non-receptor type 22 (PTPN22) alleviated thyroid dysfunction in Graves’ disease by modulating Th17/Treg balance through downregulation of the Lck/Zap70 signaling axis.